Le Lézard
Classified in: Health
Subject: FDA

FDA Approval of First Twice-Daily, Nano-Milled Ocular Corticosteroid


HARLEYSVILLE, Pa., Jan. 22, 2019 /PRNewswire/ -- Alliance Contract Pharma (ACP) is pleased to announce that one of our clients has received FDA approval for the first twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. This product represents a breakthrough in post-surgery care that can help increase the rate of successful outcomes.

ACP supported the development of this product through a range of phases: formulation development, clinical supply, process validation, FDA inspection and approval, and launch.

"The most rewarding aspect of the years of quality-driven hard work, is seeing the success of the client's FDA approval and the positive impact on the company's future," says Benjamin W. Reed, Vice President, Manufacturing. "The thoughtful determination through all aspects of the drug life cycle enabled the ease of commercialization. We look forward to helping our other clients repeat this cycle with their own products."

ACP develops and manufactures a wide range of dosage forms, from discovery to distribution. We offer a cost-effective, scale optimization experience from prototype batches to commercial scale. Our facility is audited by European Union Quality Personnel and FDA inspectors for multiple processes.

ACP is proud to have contributed to this recent milestone in ocular care and looks forward to offering its experience to future breakthroughs.

About Alliance Contract Pharma
Alliance Contract Pharma CDMO is a privately owned contract manufacturing pharmaceutical company that was incorporated in 2008.

We are a leader in the pharmaceutical industry, providing our customers with value-added analytical laboratory and manufacturing contract services. These include liquid-filled capsules, nano milling suspensions, and terminally sterilized injectables in our ISO 7 & ISO 8 cleanroom suites. We manufacture APIs/HPAPIs from formulation to commercial scale. We offer analytical method development, qualification and validation and your API, in-process or finished product, as well as ICH stability storage.

Our pledge is to establish long lasting relationships with all of our customers by exceeding their expectations and gaining their trust, by always providing the highest quality service at an economical cost.

 

SOURCE Alliance Contract Pharma


These press releases may also interest you

at 10:00
Iris Wellness Group has introduced an Outpatient Drug and Alcohol Detox Program in Chattanooga, TN, offering personalized care for individuals grappling with addiction. Launched on April 15th, 2024, this unique detox program allows patients to...

at 10:00
CREO Inc., the preferred consultancy to the world's most promising companies that seek to improve human health, today announced that Mike Townley, President and Co-Founder, has been honored with...

at 10:00
PatientRightsAdvocate.org filed an amicus brief in the case of Secretary Julie A. Su, Acting Secretary of Labor v. Blue Cross and Blue Shield (BCBS) of Minnesota, arguing that their motion to dismiss the case should be denied on the basis that BCBS...

at 09:38
The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility...

at 09:38
New platform and surgery center investment adds advanced facility capabilities to specialty care network, strengthening in-person treatment and attracting leading orthopedic surgeons and physiciansWith Theater launch, value-based MSK care visionary...

at 09:34
The below resolutions were passed at Medicover's annual general meeting (the "AGM") held today on 26 April 2024. Election of the board of directors and auditor The AGM resolved, in accordance with the proposal from the nomination committee, that the...



News published on and distributed by: